Traxis Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Traxis Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-20,000	Closed	-$1.6M	–	34
2013 Q2	$1.6M	Buy	+20,000	New	+$1.47M	1.24%	43

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Traxis Partners's VRTX Position: Q3 2013 in Review

Traxis Partners sold out of Vertex Pharmaceuticals (VRTX) in Q3 2013, closing a stake of 20,000 shares — an estimated $1.6M sold.

Traxis Partners first reported a position in VRTX in Q2 2013 and held it in 1 quarter. The position peaked at $1.6M in Q2 2013. 403 funds tracked by Wall St. Rank hold VRTX as of Q3 2013.

Traxis Partners reported no remaining Vertex Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
Traxis Partners sold 20,000 Vertex Pharmaceuticals shares in Q3 2013, an estimated $1.6M.
Traxis Partners first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 1 quarter.
Traxis Partners's Vertex Pharmaceuticals position peaked at $1.6M in Q2 2013.
403 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2013.

Based on Traxis Partners's 13F filing for Q3 2013.